Serum lipid profile changes predict neurodegeneration in interferon-beta 1a-treated multiple sclerosis patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10360784" target="_blank" >RIV/00216208:11110/17:10360784 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/17:10360784

Výsledek na webu

<a href="http://dx.doi.org/10.1194/jlr.M072751" target="_blank" >http://dx.doi.org/10.1194/jlr.M072751</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1194/jlr.M072751" target="_blank" >10.1194/jlr.M072751</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Serum lipid profile changes predict neurodegeneration in interferon-beta 1a-treated multiple sclerosis patients

Popis výsledku v původním jazyce

The purpose of this work was to determine whether changes in cholesterol profiles after interferon- (IFN-)1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 +/- 7.8 years, 63% female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were obtained at baseline, 1 month, 3 months, and every 6 months thereafter. IFN-1a initiation caused rapid decreases in serum HDL-C, LDL-C, and TC within 1 month of IFN-1a initiation (all P &lt; 0.001) that returned slowly toward baseline. In predictive mixed model analyses, greater percent decreases in HDL-C after 3 months of IFN-1a treatment initiation were associated with less brain atrophy over the 4 year time course, as assessed by percent brain volume change (P &lt; 0.001), percent gray matter volume change (P &lt; 0.001), and percent lateral ventricle volume change (P = 0.005). Decreases in cholesterol biomarkers following IFN-1a treatment are associated with brain atrophy outcomes over 4 years. Pharmacological interventions targeting lipid homeostasis may be clinically beneficial for disrupting neurodegenerative processes.

Název v anglickém jazyce

Serum lipid profile changes predict neurodegeneration in interferon-beta 1a-treated multiple sclerosis patients

Popis výsledku anglicky

The purpose of this work was to determine whether changes in cholesterol profiles after interferon- (IFN-)1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 +/- 7.8 years, 63% female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were obtained at baseline, 1 month, 3 months, and every 6 months thereafter. IFN-1a initiation caused rapid decreases in serum HDL-C, LDL-C, and TC within 1 month of IFN-1a initiation (all P &lt; 0.001) that returned slowly toward baseline. In predictive mixed model analyses, greater percent decreases in HDL-C after 3 months of IFN-1a treatment initiation were associated with less brain atrophy over the 4 year time course, as assessed by percent brain volume change (P &lt; 0.001), percent gray matter volume change (P &lt; 0.001), and percent lateral ventricle volume change (P = 0.005). Decreases in cholesterol biomarkers following IFN-1a treatment are associated with brain atrophy outcomes over 4 years. Pharmacological interventions targeting lipid homeostasis may be clinically beneficial for disrupting neurodegenerative processes.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Lipid Research

ISSN

0022-2275

e-ISSN

—

Svazek periodika

58

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

403-411

Kód UT WoS článku

000395108900010

EID výsledku v databázi Scopus

2-s2.0-85011284377